Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - insúlín glargine, lixisenatide - sykursýki, tegund 2 - lyf notuð við sykursýki - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Evropská unie - islandština - EMA (European Medicines Agency)

csl behring gmbh - mönnum storknun þáttur viii, mönnum von willebrand þáttur - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand sjúkdómur (vwd)fyrirbyggja og meðferð blæðing eða skurðaðgerð blæðingar í sjúklinga með vwd, þegar desmópressín (ddavp) meðferð einn er ófullnægjandi eða handa. dreyrasýki (meðfædda þáttur-viii skort)fyrirbyggja og meðferð blæðingar í sjúklinga með dreyrasýki a.

Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - litlaræxli - Æxlishemjandi lyf - meðferð við krabbameini í ristli með endaþarmi (mcrc).

Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - liðagigt, liðagigt - Ónæmisbælandi lyf - kevzara ásamt stendur (metÓtrexati) er ætlað til meðferð við nokkuð að alvarlega virka liðagigt (ra) í fullorðinn sjúklingum sem hafa brugðist ekki nægilega til, eða hverjir eru þola einn eða fleiri sjúkdómur breyta gegn gigt lyf (sjúkdómstemprandi). kevzara má gefa sem einlyfjameðferð ef um er að ræða óþol fyrir mtx eða þegar meðferð með mtx er óviðeigandi.

Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - umboðsmenn fyrir húðbólgu, að undanskildu barkstera - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - insúlín lispró - sykursýki - lyf notuð við sykursýki - fyrir meðferð fullorðna og börn með sykursýki sem þurfa insúlín til að viðhalda eðlilegt glúkósa homeostasis. insúlín lispró sanofi er einnig ætlað til upphafs stöðugleika sykursýki.

Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - insúlín aspart - sykursýki - lyf notuð við sykursýki - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mergæxli - Æxlishemjandi lyf - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Evropská unie - islandština - EMA (European Medicines Agency)

sanofi winthrop industrie - insúlín aspart - sykursýki - lyf notuð við sykursýki - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

Evropská unie - islandština - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - Ónæmiskerfið sera og mótefni, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.